激素治疗下前列腺体积缩小动力学:时机及对外照射放疗的影响
该系统综述遵循PRISMA指南,纳入35项临床研究,评估非转移性前列腺癌患者激素治疗期间前列腺体积变化及其对外照射放疗计划和实施的影响。结果显示前列腺体积在激素治疗前三个月缩小最显著(可达35%),缩小程度随外照射放疗启动时机和分割方案而异。结论强调需将体积缩小时间线整合入放疗流程。
要点
- 激素治疗前三个月前列腺体积缩小最显著,可达35%。
- 体积缩小程度随外照射放疗启动时机和分割方案不同而变化。
- 高精度技术如SBRT或DIL推量需考虑前列腺体积动力学。
核心结论
- 前列腺体积在激素治疗早期缩小最明显,需同步影像与外照射放疗计划。
- 对于高精度技术(如SBRT或DIL推量),考虑体积动力学至关重要。
- 临床实践应朝将前列腺体积缩小时间线整合入外照射放疗流程的方向发展。
研究设计与样本
- 遵循PRISMA指南的系统综述,纳入评估非转移性前列腺癌患者激素治疗下前列腺体积变化的临床研究。
- 采用MRI、CT、TRUS追踪最长25个月治疗期间的前列腺体积,排除临床前研究和挽救治疗病例。
- 因方案和方法学异质性,数据采用描述性综合。
主要发现
- 在35项研究中,前列腺体积在激素治疗下呈对数衰减,前三个月缩小最显著(可达35%)。
- 外照射放疗期间体积缩小程度随放疗启动时机和分割方案而异,常规分割方案中变化更大。
- 初始前列腺体积与缩小率之间呈弱相关。
临床怎么用
- 临床应依据激素治疗后前列腺体积缩小的时间线来协调影像采集和外照射放疗计划。
- 对SBRT或DIL推量等高精度技术,需将体积动力学纳入计划设计。
局限性
- 纳入研究的影像协议存在异质性。
- 缺乏正式的偏倚评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Understanding how hormonal treatment affects prostate volume is essential for optimizing external beam radiotherapy (EBRT) planning in localized prostate cancer. The study aimed to characterize the kinetics of prostate volume reduction during hormonal therapy and assess its implications for EBRT delivery and planning strategies. METHODS AND MATERIALS: A systematic review following PRISMA guidelines was conducted. Clinical studies assessing prostate volume changes under hormonal therapy in non-metastatic prostate cancer patients were included. Imaging modalities (MRI, CT, TRUS) were used to track prostate volume over treatment durations of up to 25 months. The review excluded preclinical studies and salvage therapy cases. Data were synthesized descriptively due to heterogeneity in regimens and methodologies. RESULTS: Across 35 studies, prostate volume followed a logarithmic decay under hormonal treatment, with the most significant reductions occurring in the first three months (up to 35%). The extent of volume reduction during EBRT varied by EBRT initiation timing and fractionation scheme, with greater changes observed in normofractionated regimens. A weak correlation was found between initial prostate volume and reduction rate. Limitations included heterogeneity in imaging protocols and lack of formal bias assessment. CONCLUSIONS: Prostate volume reduction is most pronounced early in hormonal treatment, emphasizing the need to synchronize imaging and EBRT planning. For high-precision techniques (e.g., SBRT or DIL boosting), accounting for volume kinetics is critical. Clinical practice should evolve toward integrating prostate volume reduction timelines into EBRT workflows.
引用
- Ghannam Y, Pasquier D, Terlizzi M, et al. Kinetics of prostate volume reduction under hormonal treatment: Timing and impact on external beam radiotherapy - A PRISMA-Compliant systematic review. Clin Transl Radiat Oncol. 2026. PMID: 41756145. doi:10.1016/j.ctro.2026.101129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。